Three cancer stocks
Cancer is one of the most interesting areas of work of the ASX’s growing cohort of life sciences companies. Here are three of the fascinating stories emerging from this area.
Investment analysis, share recommendations, and market insights.
Cancer is one of the most interesting areas of work of the ASX’s growing cohort of life sciences companies. Here are three of the fascinating stories emerging from this area.
Risks aside (and the faint hearted should read this article carefully), here are two new ETFs, one global, one local, that look well-suited to exploit conditions of higher market volatility this decade.
In our “HOT” stock article today, Michael Gable, Managing Director of Fairmont Equities, says he’s still bullish on gold and because the trend looks positive for Resolute Mining (RSG), he thinks at current levels RSG is a buying opportunity.
The history of stock markets crashing and then bouncing back big time says we should believe this rally has legs, but should we be thinking “this time it’s different”? Should I be investing for growth or going defensive right now?
Today I want to address two of the most widely asked questions by investors: Why can’t the market sell CBA? And Why is this bank so expensive? And I tell you how I think you should play CBA!
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk at Morgans, explains why Morgans reiterates its ADD rating for Aristocrat Leisure's (ALL).
Here are three stocks poised to smash through the $20 level in share price – in the cases of Orica and Northern Star, heading back above $20.
Some overseas royalty companies have been excellent investments and look like a good bet in volatile markets. Although having a low market profile, they can be attractive long-term investments. Here are two royalty plays that could be sources of income for long-term investors.
In our “HOT” stock article today, Michael Gable, Managing Director of Fairmont Equities, says he sees bullish signs for BHP.
Today I’m putting last Saturday’s star performing stocks under the analysts’ microscope to see if the gains are a sign of better returns to come. Three out of four of these look very interesting.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.